
Investigational MK-1084 Demonstrates Antitumor Activity in Phase I Trial for Colorectal and Non-Small Cell Lung Cancers
Key takeaways Early-phase trial design should anticipate combination therapy pathways, as seen with MK-1084 across multiple arms. Safety and tolerability remain primary endpoints, even when exploring novel mutation-specific therapies like KRAS G12C …